U.S. scientists found that a new test was 87% accurate in pinpointing who among patients with early memory problems would likely develop Alzheimer's disease. The test works by quantifying the concentration of amyloid beta 42 polypeptide and the amount of the tau protein in spinal fluid. The technique will enable scientists to improve the clinical trials of Alzheimer's drugs, a researcher said.

Full Story:

Related Summaries